A recent case–control study involving 2562 patients revealed that exposure to GLP-1-RAs for 1–3 years is associated with an increased risk of thyroid cancer (hazard ratio (HR) 1.58, 95% CI 1.27–1.95), and specifically medullary thyroid cancer (HR 1.78, 95% CI 1.04–3.05) [9,10]. Here, GLP1R is linked to medullary thyroid gland carcinoma.